Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Sep;23(9):1417-1421.
doi: 10.1016/j.bbmt.2017.05.035. Epub 2017 Jun 9.

Current Use and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza  1 , Stephanie Lee  2 , Xiaochun Zhu  3 , Marcelo Pasquini  4
Affiliations
Editorial

Current Use and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza et al. Biol Blood Marrow Transplant. 2017 Sep.

Abstract

Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve. We report on general overall survival by indication, by disease status at transplantation, and by transplant type. This report provides a current perspective on transplantation activity in the United States with a focus on recent trends in alternative donors and contemporary transplantation practices.

Keywords: HCT activity; Trends; US.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests

The authors have no conflicts to disclose

Figures

Figure 1
Figure 1
Estimated annual number of HCT in the United States
Figure 2
Figure 2. Allogeneic transplants in the United States by donor type
MRD-matched related donor; MMRD-mismatched related donor; MUD-BM/PB-matched unrelated donor-bone marrow/peripheral blood
Figure 3
Figure 3
A. Adult HCT activity in the US (N=19,733), 2015 PCD-plasma cell disorders; NHL-non-Hodgkin Lymphoma, AML-acute myelogenous leukemia; HD-Hodgkin’s disease; ALL- acute lymphoblastic leukemia; MDS/MPN- myelodysplastic syndrome/myeloproliferative neoplasms; CLL- chronic lymphocytic leukemia; NMD- non-malignant diseases B. Pediatric HCT activity in US (N=1,906), 2015 NHL- non-Hodgkin Lymphoma, AML- acute myelogenous leukemia; HD- Hodgkin’s disease; ALL- acute lymphoblastic leukemia; MDS/MPN- myelodysplastic syndrome/myeloproliferative neoplasms; CLL- chronic lymphocytic leukemia; NMD- non-malignant diseases
Figure 3
Figure 3
A. Adult HCT activity in the US (N=19,733), 2015 PCD-plasma cell disorders; NHL-non-Hodgkin Lymphoma, AML-acute myelogenous leukemia; HD-Hodgkin’s disease; ALL- acute lymphoblastic leukemia; MDS/MPN- myelodysplastic syndrome/myeloproliferative neoplasms; CLL- chronic lymphocytic leukemia; NMD- non-malignant diseases B. Pediatric HCT activity in US (N=1,906), 2015 NHL- non-Hodgkin Lymphoma, AML- acute myelogenous leukemia; HD- Hodgkin’s disease; ALL- acute lymphoblastic leukemia; MDS/MPN- myelodysplastic syndrome/myeloproliferative neoplasms; CLL- chronic lymphocytic leukemia; NMD- non-malignant diseases
See this image and copyright information in PMC

References

    1. Gratwohl A, Pasquini MC, Aljurf MD, Confer DL, Baldomero H, Bouzas LF, et al. Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT) Blood. 2013;122(21):2133.
    1. D’Souza A, Zhu X. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides. 2016 Available at: http://www.cibmtr.org. In, 2016.
    1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009;15(12):1628–1633. doi: 10.1016/j.bbmt.2009.07.004. - DOI - PMC - PubMed
    1. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009;15(3):367–369. doi: 10.1016/j.bbmt.2008.12.497. - DOI - PMC - PubMed
    1. 57th ASH Annual Meeting and Exposition. Orlando, FL: 2015. Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55–64 Years of Age. Blood, 2015.

Publication types

MeSH terms